Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 229

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 229
---
February 12, 2025, and certain other conditions, including the satisfaction of the $2.5 million minimum stockholders’ equity requirement
for continued listing on the Nasdaq Capital Market.

In addition, as previously
disclosed, from November 2024 through September 30, 2025, the Company raised approximately $4.4 million of net proceeds from its equity
line of credit entered into November 2024, and an additional approximately $4.2 million of net proceeds from its public offering of shares
of common stock, pre-funded warrants and warrants to purchase shares of common stock that closed on February 7, 2025 (the “February
2025 Offering”). As a result of such capital raising activities and the proceeds of the Private Placement received on the First
Closing Date, as well as successful negotiations with certain service providers to reduce outstanding balances payable, the Company received
a notification letter from Nasdaq on May 7, 2025, stating that the Company had regained compliance with the Nasdaq continued listing standard
under Nasdaq Listing Rule 5550(b)(1), which requires, among other things, that the Company maintain at least $2.5 million in stockholders’
equity.

36

On June 11, 2025, we received
a Bid Price Requirement Letter notifying us that, for the 30 consecutive business day period between April 25, 2025 through June 9, 2025,
the closing bid price for our Common Stock was below the minimum $1.00 per share required for continued listing on The Nasdaq Capital
Market set forth in Nasdaq Listing Rule 5550(a)(2), which is required for continued listing of the Common Stock on Nasdaq. We timely appealed
the delisting determination by requesting a hearing before the Nasdaq Panel. Such request for a Nasdaq Panel hearing stayed the suspension
of the Company’s securities. On July 7, 2025, Nasdaq informed us that they had determined that we have regained compliance with
the Bid Price Requirement and were therefore in compliance with the continued listing requirements. As a result, Nasdaq canceled the hearing
and the Common Stock will continue to be listed and traded on the Nasdaq Capital Market, subject to maintaining all listing standards.

On August 28, 2025, we received a letter from
the staff at the Nasdaq Listing Qualifications department notifying us that such staff had determined that we do not comply with the Stockholders’
Equity